Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

24.17 +0.22 (+0.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 686,987
Open 23.69
Bid (Size) 24.10 (2)
Ask (Size) 24.30 (2)
Prev. Close 23.95
Today's Range 23.60 - 24.48
52wk Range 13.84 - 51.59
Shares Outstanding 41,735,557
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Is Asana (ASAN) Stock Up 24% Today?
Asana (ASAN) stock is on the rise Thursday as investors react to the CEO share purchase plans and its latest earnings report. 
Via InvestorPlace
ETSY Stock Falls on Double Downgrade
Etsy (ETSY) stock is falling on Thursday after the e-commerce company's shares were hit with a double downgrade from Jefferies. 
Via InvestorPlace

Performance

YTD
-12.93%
-12.93%
1 Month
-4.95%
-4.95%
3 Month
-15.70%
-15.70%
6 Month
-46.51%
-46.51%
1 Year
-39.83%
-39.83%

More News

Read More
3 Short-Squeeze Stocks to Keep on Your Radar
Via InvestorPlace
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
Via InvestorPlace
Why Cassava Sciences Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
3 Big Reasons to Sell Cassava Sciences Stock Right Now
Via The Motley Fool
If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Down 20% Today?
Via InvestorPlace
Tesla, Apple, Cassava Sciences, MongoDB, Asana: Why These Five Stocks Are Drawing Investors' Attention Today?
Via Benzinga
Why Cassava Sciences Stock Is Surging After Hours
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via Globe NewsWire
3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End
Via InvestorPlace
$100 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
From Cassava Sciences, Inc.
Via Globe NewsWire
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Via MarketBeat
Exposures Product Safety
Tesla, Amazon, Microsoft, Cassava Sciences, Intuitive Surgical: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Cassava Sciences Stock Is Diving: What's Going On?
Via Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Cassava Sciences Shares Fall As Alzheimer's Candidate Worsens Patients With Moderate Disease
Via Benzinga
Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors
Via Investor's Business Daily
3M, Magna International And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast
Via Benzinga
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.